Management Company

Toshio Fujimoto, MD. MBA. is the Chief Executive Officer of iPark Institute Co., Ltd. Before iPark Institute Co., Ltd. took over the business from Takeda Pharmaceutical Company Limited (Takeda) in 2023, he was the General Manager of Shonan Health Innovation Park (Shonan iPark) since he joined Takeda in 2017. Prior to joining Takeda, he worked at Eli Lilly Japan to oversee the whole R&D function as Vice President, Medicines Development Unit. Earlier in his career, he was a thoracic surgeon and worked in multiple hospitals in Japan, Germany, and the US.

Hiroyasu Mitsui is the Board of Directors of iPark Institute Co., Ltd. After engaging in real estate development and investment management for about 20 years, he joined Mitsubishi Corp. - UBS Realty Inc. (currently KJR Management) in 2015. He has experience in managing a wide range of industrial real estate, including logistics facilities, factories, R&D facilities, and data centers owned by Industrial & Infrastructure Fund Investment Corporation, and has been in charge of the management of Shonan iPark since 2020.

Head, R&D Japan Region, Takeda Pharmaceutical Company Limited Program Officer for T-CiRA Program. After engaging in molecular psychopharmacological research at the National Center for Psychiatry and Neurology (at that time), held positions such as research and medical affairs at local and global pharmas such as Mitsubishi Tanabe Pharma Corporation, AbbVie, and Novartis. Joined Takeda in April 2019 and assumed the current position in April 2023. Cross-appointed to Professor, Comprehensive Research Organization, Waseda University.

Attorney at law admitted in Japan and New York. Takuji Nozaka is the Statutory Auditor of Directors of iPark Institute Co., Ltd since 2023. After working for a few law firms for 8 years in total, he worked for the Inspection Bureau of the Financial Services Agency for 2 years as a fixed-term official. After serving as the head of the legal & compliance department in other 2 asset management companies for 8 years in total, he joined Mitsubishi Corp. - UBS Realty Inc. (currently KJR Management) in 2019 as the head of the legal & compliance department.

Takahiro Hagisako leads Corporate Strategy & Planning at iPark Institute Co., Ltd. with his diverse management experience in the life science industry. Prior to joining Shonan iPark in 2020, he has worked for global healthcare companies, government agencies, consulting firms, pharmaceutical companies, and biotech start-ups.

Keisuke Watanabe leads Public Affairs at iPark Institute Co. Ltd., leveraging years of sales and liaison experience at Takeda Pharmaceutical Company Limited Prior to joining Shonan iPark's operations in 2018, he worked at Takeda Pharmaceutical Company Limited in the sales department, marketing department GP team, anti-cancer group, product strategy department, and external relations department.

Koki Nakagawa leads Commercial & Business Development and Communications, bringing extensive experience in sales, business development, and venture investment in the life science and healthcare sectors. Prior to joining Shonan iPark in 2021, he worked for a pharmaceutical company, an investment bank, a general trading company, a public-private fund, and a medical device manufacturer.

After more than 20 years of career in the aviation industry, material manufacturer, and a general lifestyle company, she was appointed to the communications department of iPark Institute Co., Ltd. in October 2023. With experience in sales, marketing communications, and public relations, she is currently focusing on branding for Shonan iPark and iPark Institute Co., Ltd.

Nobuhito Yukuhiro leads Facility Management of Shonan iPark at iPark Institute Co. Ltd., drawing on his experience in research and facility operations management. Prior to joining Shonan iPark in 2018, he worked at Takeda Pharmaceutical Company Limited in the research department for CNS drug discovery and then in the research management department.